Compare Smith & Nephew plc (SNN) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Spotify Technology — how do they compare? Smith & Nephew plc trades at $27.23 (market cap $11.10B), while Spotify Technology trades at $528.03 (market cap $108.22B). The key difference: Spotify Technology is far larger — about 9.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Spotify Technology for 111 Days on average.
| SNN | SPOT | |
|---|---|---|
Market Cap | $11.10B | $108.22B |
Volume | 1,051,703 | 1,655,796 |
Sector | Health | Media |
52-Week High | $37.17 | $692.04 |
52-Week Low | $26.42 | $412.75 |
Typical Hold Time | 120 Days | 111 Days |
Enterprise Value | $14.13B | $98.23B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Spotify (SPOT) trades at $512.92, up 5.08% with strong bullish momentum. The stock shows robust fundamentals with revenue growth from $17.19B in 2025 to projected $18.1B in 2026, while net income margin expanded to 18.43%. Technical indicators signal bullish sentiment with price above key support at $497. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending.
Outlook remains positive with analyst consensus target of $608.18 representing 18.6% upside. Key opportunities include gross margin expansion and new monetization tools, while risks involve competitive pressures and market volatility. Wall Street maintains strong buy sentiment with 62% of analysts recommending purchase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
